Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 6Completed 3Withdrawn 2Unknown 2Terminated 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Lymphocytic, Chronic, B-Cell 7Myelodysplastic Syndromes 6Hematologic Neoplasms 6Multiple Myeloma 5Leukemia 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma 4Recurrence 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Biphenotypic, Acute 3Breast Neoplasms 3Stomach Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic 2Hematologic Diseases 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × fludarabine × Clear all
NCT04093648 2020-05-20

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Baylor College of Medicine

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT02702960 2018-06-15

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡